Face to face: Ex-Novartis manager takes two-step approach to women's health at Lumavita
This article was originally published in Scrip
Many pharmaceutical and biotech companies devote themselves to the discovery and development of novel drugs for unmet medical needs. However, with R&D costs and regulatory hurdles multiplying, and much of the low-hanging therapeutic fruit already picked, a growing number of firms are taking a different, pragmatic approach. They are looking in a new light at existing compounds that may have been dropped in development for reasons that are no longer insuperable, or even withdrawn from the market. One such firm is Lumavita, whose CEO Nicholas Benedict spoke to Scrip's companies editor Eleanor Malone.